Inuver

Beclometasone dipropionate, the active ingredient in Inuver, is an inhaled corticosteroid/long‑acting β2‑adrenergic agonist presented as an inhalation aerosol for inhalation use. It treats asthma and chronic obstructive pulmonary disease in adults and children as prescribed by a healthcare professional.

GNH USA supplies Inuver as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across Europe, Asia, Africa and the Americas, ensuring consistent quality and regulatory compliance for global respiratory care markets throughout and beyond continents.

Inuver, a combination inhaled corticosteroid and long‑acting β2‑agonist, is used to manage obstructive airway diseases. - Asthma: improves symptom control, reduces frequency of exacerbations, and decreases need for rescue medication. - Chronic obstructive pulmonary disease (COPD): enhances bronchodilation, alleviates dyspnea, and helps prevent disease worsening. - Persistent airway obstruction: provides maintenance therapy to sustain lung function and limit flare‑ups.

Inuver may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Throat irritation or soreness - Hoarseness or voice change - Oral candidiasis (thrush) - Cough Serious or Rare Side Effects: - Paradoxical bronchospasm - Adrenal suppression - Severe allergic reaction (anaphylaxis)

Before using Inuver, consider the following precautions: - Assess disease severity before initiating therapy. - Monitor lung function and symptom control regularly. - Use a spacer device and rinse mouth after inhalation to reduce local effects. - Avoid abrupt discontinuation; taper under medical supervision if needed. - Caution in patients with cardiovascular disorders or arrhythmias. - Store at room temperature: keep in original container, protect from moisture and heat.

Inuver can interact with other medicines; review the following categories. Major Interactions (Avoid): - Beta‑blockers: may diminish bronchodilator effect and cause bronchospasm. - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): increase systemic exposure to beclometasone. - Monoamine oxidase inhibitors: potential additive cardiovascular effects. Moderate Interactions (Monitor Closely): - Theophylline: may increase risk of tachycardia. - Diuretics: may enhance hypokalemia risk. - Anticholinergic bronchodilators: monitor for additive bronchodilation. - Antihistamines: watch for increased sedation. - Other inhaled corticosteroids: avoid overlapping high‑dose steroid exposure.